The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial
2018
Abstract: Irritable bowel syndrome (IBS) is a common disorder in gastrointestinal system and impairs the quality of life of the patients. Clostridium butyricum (CB) is a probiotics that has been used in several gastrointestinal diseases. The efficacy of CB in treating IBS is still unknown. This prospective, multi-centre, randomized, double-blind, placebo-controlled trial aimed to assess the efficacy and safety of CB in treating diarrhea-predominant IBS (IBS-D) and analyze the fecal microbiota after treatment. Two hundre… Show more
Search citation statements
“…Overall, there were a total of 4,321 patients with IBS, of which 59.5% were female. In terms of IBS subtypes, six RCTs included patients with IBS-D, one with IBS-C and one with both IBS-D and IBS-M. [26][27][28][29][30][31][32][33] The remaining trials included patients with all subtypes. With regards to location, the majority of the trials were conducted in Europe (n = 18) followed by Asia (n = 13).…”
Section: Resultsmentioning
See 2 more Smart Citations
“…Overall, there were a total of 4,321 patients with IBS, of which 59.5% were female. In terms of IBS subtypes, six RCTs included patients with IBS-D, one with IBS-C and one with both IBS-D and IBS-M. [26][27][28][29][30][31][32][33] The remaining trials included patients with all subtypes. With regards to location, the majority of the trials were conducted in Europe (n = 18) followed by Asia (n = 13).…”
Section: Resultsmentioning
“…With regards to location, the majority of the trials were conducted in Europe (n = 18) followed by Asia (n = 13). [26][27][28][29][30][31][32][33] The remaining two RCTs were based in South Africa and the USA, respectively. 34,35 The Rome I criteria were used for diagnosis in two trials, while the Rome II criteria were used in 11 trials.…”
Section: Resultsmentioning
See 1 more Smart Citation
“…Some Clostridium species are considered as pathogens, such as C. difficile [51]. On the other hand, C. butyricum, which belongs to C. perfringens group, is probiotic bacteria able to reduce intestinal inflammation by improving the mucosal barrier function and modulating immune responses [52].…”
Section: Discussionmentioning
“…Probiotic bacteria are live microorganisms that give a health benefit to the host. In practice, probiotics can improve the balance of the intestinal microbiota ecosystem of the host, which is beneficial in treating a variety of infant conditions, including infant diarrhea, upset stomach, and eczema, and many health conditions of preterm infants (2,3). Here, we present the complete annotated genome sequence of Clostridium butyricum strain DKU_butyricum 4-1, isolated from infant feces.…”
mentioning